Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dillon

Showing results (551-560 of 576) with videos related to

Pageof 58
Sort By:
Cell Host & Microbe|June 21, 2016
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A VirusShoko Nogusa, Roshan J Thapa, Christopher P Dillon, et al.
AJNR. American Journal of Neuroradiology|August 29, 2024
Spinal CSF Leaks: The Neuroradiologist Transforming CareMark D Mamlouk, Andrew L Callen, Ajay A Madhavan, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Molecular Genetics and Metabolism|July 30, 2018
Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria CentreL R Ranganath, M Khedr, A M Milan, et al.
Plos Neglected Tropical Diseases|January 19, 2012
A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoniAnna V Protasio, Isheng J Tsai, Anne Babbage, et al.
Acta Neuropathologica|November 28, 2017
Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau depositionChin Hong Tan, Chun Chieh Fan, Elizabeth C Mormino, et al.
Molecular Cancer Therapeutics|September 21, 2018
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade TherapyBruno Gomes, Gregory Driessens, Derek Bartlett, et al.
Translational Psychiatry|April 12, 2018
CXCR4 involvement in neurodegenerative diseasesLuke W Bonham, Celeste M Karch, Chun C Fan, et al.
Heart Rhythm|July 9, 2025
Leveraging a randomized trial to assess relationships between transeptal puncture, brain emboli, and migraine symptomsAdi Elias, Roderick Tung, Edward P Gerstenfeld, et al.
Scientific Reports|September 8, 2018
Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complexYi Li, Matthew J Barkovich, Celeste M Karch, et al.
Pageof 58

Showing results (551-560 of 576) with videos related to

Sort By:
Pageof 58
Cell Host & Microbe|June 21, 2016
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A VirusShoko Nogusa, Roshan J Thapa, Christopher P Dillon, et al.
AJNR. American Journal of Neuroradiology|August 29, 2024
Spinal CSF Leaks: The Neuroradiologist Transforming CareMark D Mamlouk, Andrew L Callen, Ajay A Madhavan, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Molecular Genetics and Metabolism|July 30, 2018
Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria CentreL R Ranganath, M Khedr, A M Milan, et al.
Plos Neglected Tropical Diseases|January 19, 2012
A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoniAnna V Protasio, Isheng J Tsai, Anne Babbage, et al.
Acta Neuropathologica|November 28, 2017
Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau depositionChin Hong Tan, Chun Chieh Fan, Elizabeth C Mormino, et al.
Molecular Cancer Therapeutics|September 21, 2018
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade TherapyBruno Gomes, Gregory Driessens, Derek Bartlett, et al.
Translational Psychiatry|April 12, 2018
CXCR4 involvement in neurodegenerative diseasesLuke W Bonham, Celeste M Karch, Chun C Fan, et al.
Heart Rhythm|July 9, 2025
Leveraging a randomized trial to assess relationships between transeptal puncture, brain emboli, and migraine symptomsAdi Elias, Roderick Tung, Edward P Gerstenfeld, et al.
Scientific Reports|September 8, 2018
Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complexYi Li, Matthew J Barkovich, Celeste M Karch, et al.
Pageof 58